Research programme: immune-based therapeutics - PHIGENIX
Latest Information Update: 25 Jul 2016
At a glance
- Originator PHIGENIX
- Class Antibodies; Antineoplastics; Immunotherapies; Small interfering RNA; Small molecules
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 25 Jul 2016 Preclinical trials in Prostate cancer in USA (unspecified route)